<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Zolpidem: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Zolpidem: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Zolpidem: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10057" href="/d/html/10057.html" rel="external">see "Zolpidem: Drug information"</a> and <a class="drug drug_patient" data-topicid="11157" href="/d/html/11157.html" rel="external">see "Zolpidem: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F53545531"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Complex sleep behaviors:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following the use of zolpidem. Some of these events may result in serious injuries, including death. Discontinue zolpidem immediately if a patient experiences a complex sleep behavior.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F236158"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ambien;</li>
<li>Ambien CR;</li>
<li>Edluar;</li>
<li>Intermezzo [DSC];</li>
<li>Zolpimist [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868653"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Zolpidem ODT;</li>
<li>MINT-Zolpidem ODT;</li>
<li>PMS-Zolpidem ODT;</li>
<li>PRO-Zolpidem ODT;</li>
<li>Sublinox</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1043344"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Nonbenzodiazepine Benzodiazepine Receptor Agonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812564"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Use the lowest effective dose; higher doses may be more likely to impair next-morning activities.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b81becd-da83-442a-ae50-a03db2699784">Insomnia; associated with neurodevelopmental disorders, attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Insomnia; associated with neurodevelopmental disorders, attention-deficit/hyperactivity disorder:</b> Limited data available; efficacy results variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28391425','lexi-content-ref-30674203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28391425','lexi-content-ref-30674203'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents ≤17 years: Oral: Immediate-release tablets (eg, Ambien): Usual reported dose: 0.25 mg/kg/dose at bedtime; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17957186','lexi-content-ref-19403468','lexi-content-ref-28921528','lexi-content-ref-30328648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17957186','lexi-content-ref-19403468','lexi-content-ref-28921528','lexi-content-ref-30328648'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dosing based on reported experience from an open-label, dose escalation pharmacokinetic evaluation showed zolpidem was well-tolerated in pediatric patients 2 to 18 years of age and recommended a dose of 0.25 mg/kg at bedtime for evaluation in future efficacy trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17957186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17957186'])">Ref</a></span>). However, zolpidem has <b>not</b> been shown to be effective in a randomized placebo-controlled trial (n=201) of children aged 6 to 17 years with ADHD-associated insomnia; zolpidem 0.25 mg/kg/dose (maximum dose: 10 mg) administered nightly did <b>not</b> decrease sleep latency; in addition, hallucinations occurred in 7.4% of patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19403468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19403468'])">Ref</a></span>). A prospective, randomized double-blind clinical trial of children between ages 2 to 9 years reported that zolpidem at 0.25 mg/kg (maximum dose: 10 mg/dose) was similar to midazolam with regards to anxiety scoring and inferior with regard to mask acceptance score when used as premedication for perioperative anxiety (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30328648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30328648'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729868"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, no adjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Not dialyzable.</p></div>
<div class="block dohp drugH1Div" id="F52729869"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adults, lower doses are necessary for mild to moderate impairment; avoid use in severe impairment.</p></div>
<div class="block doa drugH1Div" id="F236162"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10057" href="/d/html/10057.html" rel="external">see "Zolpidem: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6133052a-dd36-45c0-8642-7bec793a41cc">Insomnia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Insomnia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Limit long-term use (&gt;4 weeks) to cases for which nonpharmacologic treatments are not available or not effective and benefits are felt to outweigh risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27136449','lexi-content-ref-28875581']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27136449','lexi-content-ref-28875581'])">Ref</a></span>). Use of the higher dose can increase the risk of next-day impairment of driving and activities requiring full alertness.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sleep-onset insomnia: </b></p>
<p style="text-indent:-2em;margin-left:6em;">ER tablet: <b>Oral: </b>Initial: 6.25 mg (females) or 6.25 to 12.5 mg (males) immediately before bedtime with ≥7 to 8 hours of planned sleep before waking. Use lowest effective dose, not to exceed 12.5 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">IR tablet, spray, sublingual tablet: <b>Oral: </b>Initial: 5 mg (females) or 5 to 10 mg (males) immediately before bedtime with ≥7 to 8 hours of planned sleep before waking. Use lowest effective dose, not to exceed 10 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">IR capsule:<b> Oral: </b>If 5 mg of another zolpidem IR product is not effective, may increase dose to 7.5 mg (females and males) immediately before bedtime with ≥7 to 8 hours of planned sleep before waking. Use lowest effective dose, not to exceed 10 mg for IR formulations (capsules are only available in the 7.5 mg strength).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sleep-maintenance insomnia, 7 to 8 hours planned sleep:</b></p>
<p style="text-indent:-2em;margin-left:6em;">ER tablet: <b>Oral: </b>Initial: 6.25 mg (females) or 6.25 to 12.5 mg (males) immediately before bedtime with ≥7 to 8 hours of planned sleep before waking. Use lowest effective dose, not to exceed 12.5 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">IR tablet, spray, sublingual tablet (off-label use): <b>Oral: </b>Initial: 5 mg (females) or 5 to 10 mg (males) immediately before bedtime with ≥7 to 8 hours of planned sleep before waking. Use lowest effective dose, not to exceed 10 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sleep-maintenance insomnia, awakening with 4 hours planned sleep: </b>IR sublingual tablet: <b>Oral: </b>1.75 mg (females) or 1.75 to 3.5 mg (males) once per night upon awakening in the middle of the night with ≥4 hours of planned sleep remaining.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy: </b>Reduce by the smallest available dosage form every week or every other week; ER tablets and IR capsules cannot be split. For patients taking higher doses of zolpidem (eg, 10 to 12.5 mg/day) for an extended period, tapering zolpidem even more slowly in conjunction with cognitive behavioral therapy for insomnia is encouraged (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20607118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20607118'])">Ref</a></span>). Because the ER tablets and IR capsules cannot be split, the taper is generally done with IR tablets.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990838"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8458597','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8458597','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8458597','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8458597','lexi-content-ref-Manu.1'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988061"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">ER tablet:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: 6.25 mg immediately before bedtime.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">IR capsule: Mild to severe impairment: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">IR tablet:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: 5 mg immediately before bedtime.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral spray: 5 mg immediately before bedtime.</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual tablet:</p>
<p style="text-indent:-2em;margin-left:4em;">Edluar: 5 mg immediately before bedtime.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermezzo: Females and males: 1.75 mg once per night as needed. <b>Note:</b> Take in bed only if ≥4 hours left before waking and there is difficulty in returning to sleep.</p>
<p style="text-indent:-2em;margin-left:4em;">Sublinox [Canadian product]:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate impairment: 5 mg immediately before bedtime.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block arsc drugH1Div" id="F55963375"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sedative-hypnotic agents, including zolpidem, are associated with next-day <b>drowsiness</b>, and decreased mental alertness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29077902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29077902'])">Ref</a></span>). In patients taking zolpidem, these effects have led to impaired driving, <b>accidental injury</b>, and <b>trauma</b>, such as motor vehicle accidents, <b>falling</b>, <b>bone fracture</b> (including <b>femoral neck fracture</b>), and intracranial injuries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21480377','lexi-content-ref-23826304','lexi-content-ref-23456542','lexi-content-ref-22673707','lexi-content-ref-23165956','lexi-content-ref-11844004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21480377','lexi-content-ref-23826304','lexi-content-ref-23456542','lexi-content-ref-22673707','lexi-content-ref-23165956','lexi-content-ref-11844004'])">Ref</a></span>). Patients may feel fully awake, despite this impairment in mental alertness. Zolpidem is included in the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Serum concentration-related; related to the pharmacologic action (ie, sedative-hypnotic effects).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; occurs within 24 hours after dose; may occur after the first dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24931450']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24931450'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Conditions or states leading to increased serum concentrations (eg, age ≥65 years, females) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27318232','lexi-content-ref-FDA.1','lexi-content-ref-23541711','lexi-content-ref-12919178','lexi-content-ref-29077902','lexi-content-ref-22607251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27318232','lexi-content-ref-FDA.1','lexi-content-ref-23541711','lexi-content-ref-12919178','lexi-content-ref-29077902','lexi-content-ref-22607251'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent CNS depressants (eg, medications, alcohol)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent drugs that increase zolpidem concentrations (eg, CYP 3A4 inhibitors)</p>
<p style="text-indent:-2em;margin-left:6em;">• Extended-release formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sleeping less than 7 to 8 hours after zolpidem administration</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Complex sleep behaviors</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Complex sleep-related disorder </b>may occur, including<b> somnambulism</b>, and eating, driving, cooking, and having sex while sleeping have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32323442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32323442'])">Ref</a></span>). Patients usually have no recollection of these sleep-related behaviors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grzegorzewska.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grzegorzewska.2020'])">Ref</a></span>). In some cases, these behaviors led to serious injury or death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32323442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32323442'])">Ref</a></span>). Non-fatal effects were reversible upon drug discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ho.2020','lexi-content-ref-15841201']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ho.2020','lexi-content-ref-15841201'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25470097','lexi-content-ref-Grzegorzewska.2020','lexi-content-ref-32323442','lexi-content-ref-Ho.2020','lexi-content-ref-20441722','lexi-content-ref-15841201']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25470097','lexi-content-ref-Grzegorzewska.2020','lexi-content-ref-32323442','lexi-content-ref-Ho.2020','lexi-content-ref-20441722','lexi-content-ref-15841201'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically occurs 30 minutes after a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23352047','lexi-content-ref-Cubala.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23352047','lexi-content-ref-Cubala.2014'])">Ref</a></span>). May occur after years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23352047','lexi-content-ref-Ho.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23352047','lexi-content-ref-Ho.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose: May occur at any dose; more likely with higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25470097','lexi-content-ref-Grzegorzewska.2020','lexi-content-ref-Ho.2020','lexi-content-ref-20441722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25470097','lexi-content-ref-Grzegorzewska.2020','lexi-content-ref-Ho.2020','lexi-content-ref-20441722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cubala.2014','lexi-content-ref-Ho.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cubala.2014','lexi-content-ref-Ho.2020'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of serotonergic antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grzegorzewska.2020','lexi-content-ref-32323442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grzegorzewska.2020','lexi-content-ref-32323442'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of alcohol or CNS depressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25470097','lexi-content-ref-32323442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25470097','lexi-content-ref-32323442'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of CYP3A4 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32323442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32323442'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting sleep disorder (eg, obstructive sleep apnea, restless leg syndrome) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grzegorzewska.2020','lexi-content-ref-Ho.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grzegorzewska.2020','lexi-content-ref-Ho.2020'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Administration earlier than immediately before sleep (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20441722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20441722'])">Ref</a></span>)</p>
<p style="text-indent:0em;margin-left:4em;">• Substance use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grzegorzewska.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grzegorzewska.2020'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other psychiatric/behavioral effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various other psychiatric and behavioral effects (aside from <b>complex sleep-related disorder</b>; see above for more information) have been reported, including<b> hallucination</b> (visual and auditory), <b>delirium</b>, <b>abnormality in thinking</b>, increased<b> aggressive behavior</b>, <b>disinhibition</b>, bizarre behavior, <b>agitation</b>, <b>amnesia</b>, <b>anxiety,</b> and worsening of <b>depression</b> in pediatric and adult patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19403468','lexi-content-ref-21494350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19403468','lexi-content-ref-21494350'])">Ref</a></span>). These effects have occurred unpredictably in patients with and without previously diagnosed psychiatric illness or risk factors. Hallucination was reported more frequently with zolpidem than placebo in pediatric patients treated for insomnia associated with attention-deficit/hyperactivity disorder (ADHD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19403468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19403468'])">Ref</a></span>). These effects were reversible upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19403468','lexi-content-ref-21494350','lexi-content-ref-31834190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19403468','lexi-content-ref-21494350','lexi-content-ref-31834190'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21494350','lexi-content-ref-26243852','lexi-content-ref-31834190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21494350','lexi-content-ref-26243852','lexi-content-ref-31834190'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically occurs within 15 to 30 minutes after initial dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19403468','lexi-content-ref-26243852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19403468','lexi-content-ref-26243852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose: May occur at any dose; more likely with higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21494350','lexi-content-ref-26243852','lexi-content-ref-31834190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21494350','lexi-content-ref-26243852','lexi-content-ref-31834190'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21494350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21494350'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25470097','lexi-content-ref-15486596','lexi-content-ref-31834190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25470097','lexi-content-ref-15486596','lexi-content-ref-31834190'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent psychoactive medications (eg, SSRIs, opioids, other anti-anxiety or insomnia medications) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21494350','lexi-content-ref-SAMHSA.1','lexi-content-ref-31834190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21494350','lexi-content-ref-SAMHSA.1','lexi-content-ref-31834190'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent alcohol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SAMHSA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SAMHSA.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent ADHD, neurodevelopmental disorder, or other underlying psychiatric illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19403468','lexi-content-ref-31834190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19403468','lexi-content-ref-31834190'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Substance use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834190'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal ideation and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Suicidal ideation </b>and <b>suicidal tendencies</b> have occurred in patients with and without previously diagnosed psychiatric illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27609243','lexi-content-ref-26776243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27609243','lexi-content-ref-26776243'])">Ref</a></span>). May be related to zolpidem-induced “dream-like”<b> confusion</b>, bizarre behavior, <b>hallucination</b>, or paranoia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26776243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26776243'])">Ref</a></span>). Some reports have been connected to <b>complex sleep-related disorder</b> (see above for more information) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32323442','lexi-content-ref-27609243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32323442','lexi-content-ref-27609243'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27609243','lexi-content-ref-SAMHSA.1','lexi-content-ref-26776243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27609243','lexi-content-ref-SAMHSA.1','lexi-content-ref-26776243'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; typically occurs within the first 7 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27609243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27609243'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose: May occur at any dose; more likely with higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27609243','lexi-content-ref-SAMHSA.1','lexi-content-ref-26776243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27609243','lexi-content-ref-SAMHSA.1','lexi-content-ref-26776243'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of psychiatric illness (eg, anxiety, bipolar disorder, depression, schizophrenia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26776243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26776243'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent alcohol or illicit drug use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26776243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26776243'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Withdrawal symptoms following discontinuation of GABA-mediate (GABAergic) medications are generally mild and infrequent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31271339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31271339'])">Ref</a></span>). Transient rebound sleep disturbances (eg, longer sleep-onset latency and increased awakenings) may occur for 1 to 2 days after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31271339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31271339'])">Ref</a></span>). Less commonly, a <b>withdrawal syndrome</b>, with symptoms including abdominal cramps, anxiety, disorientation, dysphoria, insomnia, irritability, muscle cramps, restlessness, seizures, sweating, tremor, and vomiting may occur, especially after rapid dose decreases or abrupt discontinuation of chronic supratherapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Beyraghi.2016','lexi-content-ref-25763219','lexi-content-ref-32543994','lexi-content-ref-21448102','lexi-content-ref-31271339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Beyraghi.2016','lexi-content-ref-25763219','lexi-content-ref-32543994','lexi-content-ref-21448102','lexi-content-ref-31271339'])">Ref</a></span>). Withdrawal syndrome symptoms generally resolve within a few weeks of drug discontinuation or with resumption of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31271339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31271339'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Withdrawal; long-term therapy induces changes in the GABA<sub>A</sub> benzodiazepine receptor that decrease the effects of endogenous GABA after drug discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31271339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31271339'])">Ref</a></span>). Chronic use of supratherapeutic zolpidem doses may result in loss of receptor selectivity and benzodiazepine-like drug effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25763219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25763219'])">Ref</a></span>). Therefore, rapid dose decreases or abrupt discontinuation may mimic benzodiazepine withdrawal.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; typically occurs within 48 hours of rapid dose decrease or abrupt drug discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25763219','lexi-content-ref-32543994','lexi-content-ref-21448102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25763219','lexi-content-ref-32543994','lexi-content-ref-21448102'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factor:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic administration of supratherapeutic doses (eg, &gt;100 mg/day for months to years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Beyraghi.2016','lexi-content-ref-25763219','lexi-content-ref-32543994','lexi-content-ref-21448102','lexi-content-ref-31271339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Beyraghi.2016','lexi-content-ref-25763219','lexi-content-ref-32543994','lexi-content-ref-21448102','lexi-content-ref-31271339'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F236126"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported with oral administration, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Dizziness (1% to 12%) (Blumer 2009), drowsiness (2% to 15%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 1</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, headache (oral: 7% to 19%; sublingual: 3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Zolpidem: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">102</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">110</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">161</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">685</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">473</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort (1%), chest pain (1%), edema (≤1%), hypertension (≤1%), increased blood pressure (1%), orthostatic hypotension (≤1%), palpitations (2%), syncope (≤1%), tachycardia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (≤1%), pallor (≤1%), pruritus (≤1%), skin rash (1% to 2%), urticaria (≤1%), wrinkling of skin (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heavy menstrual bleeding (1%), hyperglycemia (≤1%), increased thirst (≤1%), menstrual disease (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (1%), abdominal tenderness (1%), anorexia (≤1%), change in appetite (1%), constipation (2%), diarrhea (1% to 3%), dysgeusia (≤1%), dyspepsia (&gt;1%), dysphagia (≤1%), flatulence (≤1%), frequent bowel movements (1%), gastroenteritis (1%) (Blumer 2009), gastroesophageal reflux disease (1%), hiccups (&gt;1%), nausea (7%), vomiting (1%), xerostomia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (≤1%), urinary incontinence (≤1%) (Blumer 2009), urinary tract infection (&gt;1%), vaginitis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (≤1%), influenza (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (1%), agitation (≤1%), amnesia (1%)<span class="lexi-table-link-container"> (<a aria-label="Amnesia table link" class="lexi-table-link" data-table-id="lexi-content-amnesia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-amnesia')">table 2</a>)</span><span class="table-link" style="display:none;">Amnesia</span>, anxiety (2% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Anxiety table link" class="lexi-table-link" data-table-id="lexi-content-anxiety" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anxiety')">table 3</a>)</span><span class="table-link" style="display:none;">Anxiety</span>, ataxia (1%)<span class="lexi-table-link-container"> (<a aria-label="Ataxia table link" class="lexi-table-link" data-table-id="lexi-content-ataxia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ataxia')">table 4</a>)</span><span class="table-link" style="display:none;">Ataxia</span>, balance impairment (2%)<span class="lexi-table-link-container"> (<a aria-label="Balance Impairment table link" class="lexi-table-link" data-table-id="lexi-content-balance-impairment" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-balance-impairment')">table 5</a>)</span><span class="table-link" style="display:none;">Balance Impairment</span>, cerebrovascular disease (≤1%), cognitive dysfunction (≤1%), confusion (&gt;1%), depersonalization (1%), depression (2%)<span class="lexi-table-link-container"> (<a aria-label="Depression table link" class="lexi-table-link" data-table-id="lexi-content-depression" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-depression')">table 6</a>)</span><span class="table-link" style="display:none;">Depression</span>, disinhibition (1%)<span class="lexi-table-link-container"> (<a aria-label="Disinhibition table link" class="lexi-table-link" data-table-id="lexi-content-disinhibition" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-disinhibition')">table 7</a>)</span><span class="table-link" style="display:none;">Disinhibition</span>, disorientation (3%), disturbance in attention (2%)<span class="lexi-table-link-container"> (<a aria-label="Disturbance in Attention table link" class="lexi-table-link" data-table-id="lexi-content-disturbance-in-attention" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-disturbance-in-attention')">table 8</a>)</span><span class="table-link" style="display:none;">Disturbance in Attention</span>, dysarthria (≤1%), eating disorder (1%; binge eating), emotional lability (≤1%), euphoria (&gt;1%), falling (≤1%), fatigue (oral: 3%; sublingual: 1%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 9</a>)</span><span class="table-link" style="display:none;">Fatigue</span>, hallucination (4%), hypoesthesia (2%), illusion (≤1%), increased body temperature (1%), insomnia (&gt;1%), intoxicated feeling (3%), lethargy (3%), malaise (≤1%), memory impairment (3%), migraine (≤1%), nervousness (≤1%), paresthesia (1%), psychomotor impairment (2%), sleep disorder (1%), speech disturbance (≤1%), stress (1%), stupor (≤1%), vertigo (2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Amnesia" frame="border" id="lexi-content-amnesia" rules="all">
<caption style="text-align:center;">
<b>Zolpidem: Adverse Reaction: Amnesia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">161</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anxiety" frame="border" id="lexi-content-anxiety" rules="all">
<caption style="text-align:center;">
<b>Zolpidem: Adverse Reaction: Anxiety</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">102</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">110</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ataxia" frame="border" id="lexi-content-ataxia" rules="all">
<caption style="text-align:center;">
<b>Zolpidem: Adverse Reaction: Ataxia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">102</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">110</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Balance Impairment" frame="border" id="lexi-content-balance-impairment" rules="all">
<caption style="text-align:center;">
<b>Zolpidem: Adverse Reaction: Balance Impairment</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">102</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">110</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Depression" frame="border" id="lexi-content-depression" rules="all">
<caption style="text-align:center;">
<b>Zolpidem: Adverse Reaction: Depression</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">102</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">110</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">161</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Disinhibition" frame="border" id="lexi-content-disinhibition" rules="all">
<caption style="text-align:center;">
<b>Zolpidem: Adverse Reaction: Disinhibition</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">102</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">110</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Disturbance in Attention" frame="border" id="lexi-content-disturbance-in-attention" rules="all">
<caption style="text-align:center;">
<b>Zolpidem: Adverse Reaction: Disturbance in Attention</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">102</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">110</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:center;">
<b>Zolpidem: Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zolpidem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">102</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">110</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sublingual</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">145</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&gt;1%), arthritis (≤1%), asthenia (1%), back pain (3% to 4%), lower limb cramp (≤1%), myalgia (4%), neck pain (1%), tremor (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Asthenopia (1%), blurred vision (2%), diplopia (&gt;1%), eye irritation (≤1%), eye pain (≤1%), eye redness (2%), scleritis (≤1%), visual disturbance (1% to 3%; including altered depth perception)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Labyrinthitis (1%), tinnitus (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (≤1%), cough (≤1%), dyspnea (≤1%), flu-like symptoms (1% to 2%), lower respiratory tract infection (&gt;1%), pharyngitis (3%), rhinitis (≤1%), sinusitis (4%), throat irritation (1%), upper respiratory tract infection (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤1%), trauma (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, arteritis, cardiac arrhythmia, circulatory shock, exacerbation of hypertension, extrasystoles, facial edema, flushing, hypotension, phlebitis, pulmonary embolism, thrombosis, varicose veins, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, bullous rash, dermatitis, furunculosis, skin photosensitivity</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, gout, hot flash, hypercholesteremia, hyperlipidemia, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Alteration of saliva, dental caries, enteritis, eructation, esophageal spasm, gastritis, hemorrhoids, increased appetite, intestinal obstruction, sialorrhea, tenesmus</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast fibroadenosis, dysuria, impotence, mastalgia, nocturia, urinary frequency, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, breast neoplasm, hyperhemoglobinemia, increased erythrocyte sedimentation rate, leukopenia, lymphadenopathy, macrocytic anemia, purpuric disease, rectal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia, increased serum alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess, herpes simplex infection, herpes zoster infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, abnormality in thinking, aggressive behavior, altered sense of smell, apathy, delusion, dementia, drug dependence, dysphasia, hypotonia, hysteria, manic reaction, myasthenia, neuralgia, neuritis, neuropathy, neurosis, numbness of tongue, pain, panic disorder, paresis, personality disorder, restless leg syndrome, rigors, sciatica, strange feeling, yawning</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hypokinesia, osteoarthritis, tendinopathy, tetany</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal lacrimation, accommodation disturbance, conjunctivitis, corneal ulcer, glaucoma, periorbital edema, photopsia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis externa, otitis media</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, polyuria, pyelonephritis, renal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, epistaxis, hypoxia, laryngitis, pneumonia, pulmonary edema, respiratory depression</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis, hepatocellular hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Complex sleep-related disorder (Harbourt 2020), delirium (Inagaki 2010), somnambulism (Inagaki 2010), suicidal ideation, suicidal tendencies, withdrawal syndrome (Wilson 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Treves 2018), femoral neck fracture (Wang 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (Chung 2013)</p></div>
<div class="block coi drugH1Div" id="F236142"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, angioedema) to zolpidem or any component of the formulation; patients who have experienced complex sleep behaviors after taking zolpidem</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Significant obstructive sleep apnea syndrome and acute and/or severe impairment of respiratory function; myasthenia gravis; severe hepatic impairment; personal or family history of sleepwalking</p></div>
<div class="block war drugH1Div" id="F236123"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Use with caution in patients with depression, particularly if suicidal risk may be present.</p>
<p style="text-indent:-2em;margin-left:4em;">• Drug misuse: Use with caution in patients with a history of substance use disorder. Risk of misuse is increased in patients with a history of or family history of alcohol or substance use disorder or mental illness.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: GABA agonists, including zolpidem, have been associated with precipitation of hepatic encephalopathy in patients with hepatic impairment. Patients with hepatic impairment do not clear zolpidem as rapidly as patients with normal hepatic function. Use with caution in patients with mild to moderate hepatic impairment; dose adjustment recommended. Avoid use of IR capsules and tablets and ER tablets in patients with severe hepatic impairment; may result in encephalopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with respiratory compromise, COPD, or sleep apnea.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated: Use with caution in debilitated patients; potential for oversedation, impaired coordination, and confusion with use; dosage adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adult patients; dose adjustment recommended. Monitor for impaired cognitive and/or motor performance, confusion, and potential for falling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Females: Dosage adjustment is recommended for females; pharmacokinetic studies involving zolpidem showed a significant increase in maximum concentration and exposure in females compared to males at the same dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: When studied off label for the management of insomnia associated with attention-deficit/hyperactivity disorder in children, a higher incidence (~7%) of hallucinations was reported. In addition, sleep latency did not decrease compared to placebo.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Symptomatic treatment of insomnia should be initiated only after careful evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7 to 10 days may indicate the need for psychiatric and/or medical illness reevaluation. Long-term use is not recommended; reevaluation of patient’s status should occur before extending treatment due to risk of abuse and dependence.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rapid onset: Because of the rapid onset of action, administer Intermezzo immediately prior to bedtime, after the patient has gone to bed and is having difficulty falling asleep, or during the middle of the night when at least 4 hours are left before waking.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878679"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block prod-avail drugH1Div" id="F58227370"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Zolpidem tartrate 7.5 mg capsules: FDA approved May 2023; anticipated availability currently unknown.</p></div>
<div class="block dosfc drugH1Div" id="F51558386"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;">Zolpimist oral spray 4.5 mL containers contain 30 actuations and 7.7 mL containers contain 60 actuations.</p></div>
<div class="block foc drugH1Div" id="F236134"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 7.5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zolpimist: 5 mg/actuation (4.5 mL [DSC], 7.7 mL [DSC]) [contains benzoic acid, propylene glycol; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ambien: 5 mg [contains fd&amp;c red #40 (allura red ac dye), polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ambien: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ambien CR: 6.25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ambien CR: 12.5 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6.25 mg, 12.5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Sublingual, Sublingual, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Edluar: 5 mg, 10 mg [contains saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Intermezzo: 1.75 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.75 mg, 3.5 mg</p></div>
<div class="block geq drugH1Div" id="F236119"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F236145"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Zolpidem Tartrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $10.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Sublingual</b> (Edluar Sublingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $16.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $16.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Sublingual</b> (Zolpidem Tartrate Sublingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.75 mg (per each): $10.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.5 mg (per each): $10.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Ambien CR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6.25 mg (per each): $25.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $25.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Zolpidem Tartrate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6.25 mg (per each): $1.61 - $6.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $1.61 - $6.12</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ambien Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $25.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $25.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zolpidem Tartrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.10 - $5.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $4.62 - $5.14</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868654"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Sublingual, Sublingual, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sublinox: 5 mg, 10 mg [contains saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block csi drugH1Div" id="F236197"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block admp drugH1Div" id="F52614036"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Immediate-release tablets (eg, Ambien): Regardless of dosage form, do not administer with or immediately after a meal (may delay onset). Zolpidem immediate-release tablets should be taken as a single dose immediately before bedtime (due to rapid onset) with at least 7 to 8 hours remaining before planned time of awakening and should not be readministered during the same night.</p></div>
<div class="block adm drugH1Div" id="F236139"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer immediately before bedtime due to rapid onset of action. Regardless of dosage form, do not administer with or immediately after a meal (may delay onset). With the exception of Intermezzo, zolpidem should be taken as a single dose at bedtime with at least 7 to 8 hours remaining before planned time of awakening and should not be readministered during the same night. Intermezzo should be taken in bed if patient awakes in the middle of the night (ie, if ≥4 hours left before waking) and there is difficulty in returning to sleep.</p>
<p style="text-indent:-2em;margin-left:2em;">IR capsule: Swallow capsule whole; do not open, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">ER tablet: Swallow tablet whole; do not divide, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablet, sublingual tablet, and oral spray formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual tablet: Place sublingual tablet under the tongue and allow to disintegrate; do not swallow or administer Edluar or Sublinox with water.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral spray: Spray directly into the mouth over the tongue. Prior to initial use, prime pump by spraying 5 times. If pump is not used for at least 14 days, reprime pump with 1 spray.</p></div>
<div class="block sts drugH1Div" id="F5659904"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">IR capsule: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">IR and sublingual tablets: Store at 20°C to 25°C (68°F to 77°F). Protect sublingual tablets from light and moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">ER tablet: Store at 15°C to 25°C (59°F to 77°F); limited excursions permitted up to 30°C (86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral spray: Store upright at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze. Avoid prolonged exposure to temperatures &gt;30°C (86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual tablet (Sublinox [Canadian product]): Store at 15°C to 30°C (59°F to 86°F); protect from light and moisture.</p></div>
<div class="block meg drugH1Div" id="F7874935"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Ambien: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F019908s40s044s047lbl.pdf%23page%3D24&amp;token=DMXjBM9%2FWy3Od%2FNNbqvArdctt9BlOSWscmWlmzhr7Fg23oGG51BB5daWpNcO8H6Rz0Nhj6NmS42PkwAvjdqOrNMFaTaae84PiXqJp2KQbEZcUy73bKVy5pLW%2BzdR5aQ3&amp;TOPIC_ID=13094" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019908s40s044s047lbl.pdf#page=24</a></p>
<p style="text-indent:-2em;margin-left:4em;">Ambien CR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F021774s021s025s028lbl.pdf%23page%3D27&amp;token=4IDulkPFInfADpOvfwPoNPJDR4xLsb%2FxHdw%2Bk2baoM5svNUrz%2B2qJoUKWMITd1QmyrH0Q2yameYSk8GDdZ%2FwvPOaJNI6yOyB56oUywB%2BuonFzR%2FOtrZbpB7Z7br%2BwpOs&amp;TOPIC_ID=13094" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021774s021s025s028lbl.pdf#page=27</a></p>
<p style="text-indent:-2em;margin-left:4em;">Edluar: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F021997s011lbl.pdf%23page%3D23&amp;token=nEYsG7e012mTr0%2FCTtTIk4g4DLB9aUt1QFC6H5mDpY7KetVcOAbQzl9u%2Fo84YczYYV1qec6v8GojfLQeC%2Bcx3Rr8uferQO1eZCVuePyRaVK1%2FdGQUBkaxvLQug8glZvv&amp;TOPIC_ID=13094" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021997s011lbl.pdf#page=23</a></p>
<p style="text-indent:-2em;margin-left:4em;">Intermezzo: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F022328s008lbl.pdf%23page%3D20&amp;token=pE7h%2FXsBQo%2F721Hl1Nf8U3ylfNvPC85SPwqV0lzSAg08GSO9DWH9r65ztEemhnDGsVjkocNIo5FQHPwnBh4NjDiVkxrBu%2BsWpSsv%2BKEVOdEHwYpTSMVhrME1xM4fQACF&amp;TOPIC_ID=13094" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022328s008lbl.pdf#page=20</a></p>
<p style="text-indent:-2em;margin-left:4em;">Zolpidem tartrate capsules: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F215721s000lbl.pdf%23page%3D27&amp;token=PQ4UQw20gZBnu%2FdLwdCR1sgdgUe4Tw9UB6FKppYWXEEh5ovLGlWIg0LIqOR74YNT%2Fw8eeYJJLop3XbhTwks4flqilnM%2FB1OdQeaXfPhcapiENb7SREwCQamITojw6Kri&amp;TOPIC_ID=13094" target="_blank"> https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215721s000lbl.pdf#page=27</a></p>
<p style="text-indent:-2em;margin-left:4em;">Zolpidem tablets: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2FZolpidem.pdf&amp;token=uCi9tQ62WBIIz89fEk4fPbF%2By%2F%2FCFbQcdYdNneyYKm3I9Pv1SCKp2u0emsPpsUft39zbwBsxHq4MK0Xe%2BneVOnVjS4QUD0Du3D7MWU4dkRA%3D&amp;TOPIC_ID=13094" target="_blank"> https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/Zolpidem.pdf</a></p>
<p style="text-indent:-2em;margin-left:4em;">Zolpimist: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F022196s012lbl.pdf%23page%3D19&amp;token=%2BverorHVwTn4DHRahXtESV%2BWkVGz5OA06FxHEQhCbj%2BxF%2FA39SEMqF6qGNB5CREiP8D1ojZvKCvHQ2jE1AxeEnHP8TTIxA3kLkTdx7s9TNG%2Bgpduti%2Frjox6%2FEFo%2B7be&amp;TOPIC_ID=13094" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022196s012lbl.pdf#page=19</a></p></div>
<div class="block usep drugH1Div" id="F53569566"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Short-term treatment of transient insomnia with difficulty of sleep initiation (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release (eg, Ambien): Short-term treatment of insomnia (with difficulty of sleep onset) (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release (eg, Ambien CR): Treatment of insomnia (with difficulty of sleep onset and/or sleep maintenance) (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual:</p>
<p style="text-indent:-2em;margin-left:4em;">Edluar: Short-term treatment of insomnia (with difficulty of sleep onset) (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermezzo: "As needed" treatment of middle-of-the-night insomnia with ≥4 hours of sleep time remaining (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral spray: Zolpimist: Short-term treatment of insomnia (with difficulty of sleep onset) (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F236204"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ambien may be confused with Abilify, ambrisentan, Ativan, Ambi 10</p>
<p style="text-indent:-2em;margin-left:4em;">Sublinox may be confused with Suboxone</p>
<p style="text-indent:-2em;margin-left:4em;">Zolpidem may be confused with lorazepam, zaleplon, Zyloprim</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Zolpidem, a nonbenzodiazepine benzodiazepine-receptor agonist hypnotic, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to adverse events similar to benzodiazepines in older adults (eg, delirium, falls, fractures) and an increase in emergency room visits, hospitalizations, and motor vehicle crashes. In addition, improvement in sleep latency and duration is minimal (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F236189"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F236128"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): May increase the serum concentration of Zolpidem. Management: Consider avoiding the combination of ciprofloxacin and zolpidem if possible. If combined, monitor for signs of zolpidem toxicity (eg, somnolence, dizziness, lethargy).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluvoxaMINE: May enhance the CNS depressant effect of Zolpidem. FluvoxaMINE may increase the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May enhance the sedative effect of Hypnotics (Nonbenzodiazepine).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: Hypnotics (Nonbenzodiazepine) may enhance the CNS depressant effect of Oxybate Salt Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: May increase the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Zolpidem.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F236154"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Maximum plasma concentration and bioavailability are decreased with food; time to peak plasma concentration is increased; half-life remains unchanged. Management: Do not administer with (or immediately after) a meal.</p></div>
<div class="block dic drugH1Div" id="F1615035"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Do not administer with or immediately after a meal (may delay onset).</p></div>
<div class="block pri drugH1Div" id="F1615032"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Zolpidem crosses the placenta (Juric 2009; Saito 2021).</p>
<p style="text-indent:0em;margin-top:2em;">According to product labeling, severe neonatal respiratory depression (requiring artificial ventilation or intratracheal intubation) and sedation have been reported following maternal use late in the third trimester. Exposed neonates should be monitored for excess sedation, hypotonia, and respiratory depression. Additional adverse effects, including low birth weight or preterm delivery, have been observed in some studies (Juric 2009; Sharma 2011; Wang 2010; Wikner 2011).</p></div>
<div class="block mopp drugH1Div" id="F53569565"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Daytime alertness; respiratory rate; behavior profile (including hallucinations and other psychiatric and/or nervous system adverse reactions, especially in pediatric patients with ADHD) (Cronin 2015).</p></div>
<div class="block pha drugH1Div" id="F236122"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Zolpidem, an imidazopyridine hypnotic that is structurally dissimilar to benzodiazepines, enhances the activity of the inhibitory neurotransmitter, γ-aminobutyric acid (GABA), via selective agonism at the benzodiazepine-1 (BZ<sub>1</sub>) receptor; the result is increased chloride conductance, neuronal hyperpolarization, inhibition of the action potential, and a decrease in neuronal excitability leading to sedative and hypnotic effects. Because of its selectivity for the BZ<sub>1</sub> receptor site over the BZ<sub>2</sub> receptor site, zolpidem exhibits minimal anxiolytic, myorelaxant, and antiseizure properties (effects largely attributed to agonism at the BZ<sub>2</sub> receptor site).</p></div>
<div class="block phk drugH1Div" id="F236141"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Tablet: Immediate release: 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Tablet: Immediate release: 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: C<sub>max</sub> and AUC is increased by ~45% in females compared to male subjects.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Immediate release: Mean C<sub>max</sub> and AUC decreased by 39% and 8%, respectively, with a high-fat, high-calorie meal compared to fasted conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release and sublingual: Rapid.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Biphasic absorption; rapid initial absorption (similar to IR product); then provides extended concentrations in the plasma beyond 3 hours post administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 6 years: 1.8 ± 0.8 L/kg (Blumer 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;6 to 12 years: 2.2 ± 1.7 L/kg (Blumer 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: 1.2 ± 0.4 L/kg (Blumer 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.54 L/kg after an IV dose (Holm 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~93%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic methylation and hydroxylation via CYP3A4 (~60%), CYP2C9 (~22%), CYP1A2 (~14%), CYP2D6 (~3%), and CYP2C19 (~3%) to 3 inactive metabolites (Holm 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tablet: Immediate release: 70% (Holm 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 6 years of age: Tablet: Immediate release: 1.8 hours (Blumer 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;6 years of age and Adolescents: Tablet: Immediate release: 2.3 hours (Blumer 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults:</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule: Immediate release: 3.7 hours (range: 1.2 to 8.3 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">Spray: ~3 hours (range: 1.7 to 8.4).</p>
<p style="text-indent:-2em;margin-left:6em;">Tablet:</p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release, Extended release: ~2.5 hours (range: 1.4 to 4.5 hours); Cirrhosis: Up to 9.9 hours; Elderly: Prolonged up to 32%.</p>
<p style="text-indent:-2em;margin-left:8em;">Sublingual: ~3 hours (range: 1.4 to 6.7 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 6 years of age: Tablet: Immediate release: 0.9 hours (Blumer 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;6 to 12 years of age: Tablet: Immediate release: 1.1 hours (Blumer 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Tablet: Immediate release: 1.3 hours (Blumer 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults:</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule: Immediate release: 1 hour; 2.8 hours with food.</p>
<p style="text-indent:-2em;margin-left:6em;">Spray: ~0.9 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablet:</p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release: 1.6 hours; 2.2 hours with food.</p>
<p style="text-indent:-2em;margin-left:8em;">Extended release: 1.5 hours; 4 hours with food.</p>
<p style="text-indent:-2em;margin-left:8em;">Sublingual: Edluar: ~1.4 hours, ~1.8 hours with food; Intermezzo: 0.6 to 1.3 hours, ~3 hours with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (48% to 67%, primarily as metabolites); feces (29% to 42%, primarily as metabolites).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance, apparent:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 6 years: 11.7 ± 7.9 mL/minute/kg (Blumer 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;6 to 12 years: 9.7 ± 10.3 mL/minute/kg (Blumer 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: 4.8 ± 2 mL/minute/kg (Blumer 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Intermezzo: Males: 4 mL/minute/kg; Females: 2.7 mL/minute/kg.</p></div>
<div class="block phksp drugH1Div" id="F51192024"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: C<sub>max</sub> and AUC were found to be 2 and 5 times higher, respectively, in hepatically compromised patients. The mean half-life in cirrhotic patients of 9.9 hours was greater than that observed in normal subjects of 2.2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet: Immediate release: </b>C<sub>max</sub>, half-life, and AUC were significantly increased when compared with results in younger adults.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet: Extended release:</b> Mean C<sub>max</sub> and mean AUC are 70.6 ng/mL and 413 ng•h/mL, respectively, while the median T<sub>max</sub> is 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: C<sub>max</sub> and AUC were higher when comparing the same dose in women with men. Women clear zolpidem from the body at a lower rate than men. In geriatric patients, clearance is similar between men and women.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F236146"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Zolonia | Zolpicalm odt</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dormi Ros | Durnit | Fulsadem | Nocte | Somit | Somit intersueno | Somnipax | Zoldem | Zolip | Zoliprox | Zolpidem teva | Zolpidem vannier</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Edluar | Ivadal | Mondeal | Zoldem | Zolpidem g.l. | Zolpidem hexal pharma | Zolpidem ratiopharm | Zolpidemtartrat Actavis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo zolpidem | Dormizol | GenRx Zolpidem | Somidem | Stilnox | Synthon zolpidem | Zolpibell | Zolpidem an | Zolpidem dr.reddy's | Zolpidem gh | Zolpidem Pharmacor | Zolpidem sandoz | Zolpimist</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Nitrest</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Stilnoct | Zolpeduar | Zolpidem | Zolpidem bexal | Zolpidem eurogenerics | Zolpidem merck-generics | Zolpidem ratiopharm | Zolpidem sandoz | Zolpidem teva generics belgium | Zolpitop</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Hypnogen | Stilnox</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Hemitartarato de zolpidem | Insonox | Lioram | Lune | Lune sl | Meditivox | Noctiden | Patz | Pidezot | Prompt | Riposo sl | Stilnox | Stilram | Stilram sl | Tartarato de zolpidem | Turno | Turno sl | Zolpaz | Zolpirest | Zolrem sl | Zoup sl | Zylinox | Zylinox sl</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Stilnox | Zoldorm | Zolpi-Med | Zolpidem 1 A Pharma | Zolpidem Actavis | Zolpidem axapharm | Zolpidem HelvePharm | Zolpidem Mepha | Zolpidem mepha teva | Zolpidem sandoz | Zolpidem spirig hc | Zolpidem Streuli | Zolpidem teva | Zolpidem winthrop | Zolpidem zentiva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Zolpinox</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Adormix | Dormosol | Hipnoton | Somnipron | Somno | Sucedal | Zaviana fs</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Jun le ning | Le tan | Nuo bin | Sai nuo sai | Stilnox</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Insodem | Solpirem | Somnil | Stilnox | Sucedal | Zimor | Zolpidem | Zolpidem humax</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adorma | Apo zolpidem | Eanox | Edluar | Hypnogen | Indren | Onirex | Sanval | Stilnox | Zolpidem | Zolpidem aurovitas | Zolpidem Orion | Zolpidem vitabalans | Zolpidem xantis | Zolpinox | Zolsana | Zonadin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Amsic | Bikalm | Edluar | Ivadal | Noctidem | Pronox | Stilnox | Zodormdura | Zoldem | Zolirin | Zolpi lich | Zolpi-Q | Zolpidem | Zolpidem 10 1a-pharma | Zolpidem Actavis | Zolpidem al | Zolpidem Aristo | Zolpidem Heumann | Zolpidem hexal | Zolpidem ratiopharm | Zolpidem sandoz | Zolpidem vitabalans | Zolpinox</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Nimadorm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Hipnatur | Intensum | Nocpidem | Nocte | Somit | Stilnox | Sucedal | Tardine | Zogno | Zolpid | Zolpidem</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Albapax | Flazinil | Stilnox | Zolpidem la sante</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Hypnogen | Stilnox | Zolpidem hexal | Zolpidem sandoz | Zolpidem vitabalans | Zolsana</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Stilnox | Zodium</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cedrol | Dalparan | Stilnox | Zolpidem acost | Zolpidem Apotex | Zolpidem aurobindo | Zolpidem aurovitas | Zolpidem bayvit | Zolpidem desgen | Zolpidem Pharmagenus | Zolpidem rimafar | Zolpidem sandoz | Zolpidem tevagen | Zolpidem vir | Zolpidem winthrop</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Edluar | Slorex | Somnor | Stella | Stilnoct | Zolpidem hexal | Zolpidem ratiopharm | Zolpidem sandoz | Zolpidem stada | Zolpidem vitabalans</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ivadal | Stilnox | Zolpidem Actavis | Zolpidem Almus | Zolpidem Alter | Zolpidem arrow | Zolpidem biogaran | Zolpidem eg | Zolpidem g gam | Zolpidem gnr | Zolpidem irex | Zolpidem ivax | Zolpidem Merck | Zolpidem qualimed | Zolpidem ratiopharm | Zolpidem RPG | Zolpidem sandoz | Zolpidem teva | Zolpidem Zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Stilnoct | Zolpidem | Zolpidem cox | Zolpidem kent | Zolpidem sandoz</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Stilnox</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo zolpidem | Euro zolpidem | Nikp zolpidem | Stilnox | Stilpidem | Syntilnox | Vicknox | Vicknox b | Zolman | Zolnox | Zolpidem sandoz</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Lunata | Sanval | Zonadin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Pidezol | Sanval | Stilnox | Zolep | Zolpidem ratiopharm | Zolpidem vitabalans | Zolsana</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Stilnox | Zolmia | Zolta | Zudem</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Nytamel | Stilnoct | Zoldem | Zolnod | Zolpidem teva</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Stilnox | Zodorm</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ambiz | Ambulax z | Dactive | Dem | Freshika z | Lopitas | Natpidem | Nidra | Nitrest | Olpid | Sedopee | Sleepwell | Sobrium | Sove | Soza | Soza er | Stilnoct | Z8 | Zappy | Zedtime | Zenex | Zleep | Zoldem | Zoldy | Zolfresh | Zolnap | Zolnyt | Zolpid | Zolpigress | Zolpinite | Zolpirest | Zolt | Zolway | Zopenta | Zozo</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Niotal | Nottem | Stilnox | Zolpeduar | Zolpidem Actavis | Zolpidem Doc G. | Zolpidem eg | Zolpidem Fidia | Zolpidem ratiopharm</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Inso n | Stilnox</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Myslee | Zolpidem tartrate ffp | Zolpidem tartrate jg | Zolpidem tartrate kog | Zolpidem tartrate Nissin | Zolpidem tartrate pfizer | Zolpidem tartrate teva | Zolpidem tartrate towa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Nitrest | Nocte | Stilnox | Zolpirex</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pharma zolpidem tartrate | Sandoz zolpidem | Sleep | Slip | Stilnox | Stilrex | Zanilo | Zolpiart | Zolpicin | Zolpid | Zolpidem | Zolpiram | Zolpium</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Stilnox</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Stilnox</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Hypnogen | Onirex | Stilnox | Zolpidem hexal | Zolpidem sandoz | Zolpidem vitabalans | Zolsana</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Stilnoct | Zolpeduar | Zolpidem eg</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Hypnogen | Stilnox | Zolpidem vitabalans | Zolpidemhexal | Zolsana</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Noctizen | Noxidem | Stilnox | Zolpidem Normon | Zolpidox</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">10 nait | Dornox | Eslinev | Nitelnoz | Nocte | Notix | Sognomel | Sonnox | Stilnox</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Anpro Zolpidem | Avonox | Sobrium | Stilnox | Torzolp | Zodenox | Zopim</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Stilnoct | Zolpidemtartr | Zolpidemtartraat | Zolpidemtartraat Actavis | Zolpidemtartraat Alpharma | Zolpidemtartraat aurobindo | Zolpidol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Stilnoct | Zolpidem | Zolpidem aurobindo | Zolpidem sandoz | Zolpidem vitabalans</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Stilnoct</span>;</li>
<li>
<span class="countryCode">(PA)</span> <span class="country">Panama</span><span class="countrySeparator">: </span><span class="drugName">Uninorm</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Somno | Stilnox | Sucedal | Viradex | Zolpidem</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Dactive | Sitinox | Stilnox | Ziohex</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ambin | Ensomie | Olida | Siesta | Slepzol | Somnia | Stilnox | Xolnox | Zolep | Zolly | Zolp | Zolpidex | Zolpimed | Zonox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo zolpin | Hypnogen | Nasen | Noxizol | Onirex | Polsen | Sanval | Stilnox | Zolpic | Zolpidem genoptim | Zolpidem vitabalans | Zolpidem vitama | Zolpigen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ambien | Edluar | Intermezzo | Zolpidem | Zolpidem Tartate | Zolpimist</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cymerion | Stilnox | Zolpidem | Zolpidem aurobindo | Zolpidem labesfal</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Somit | Stilnox | Zaviana fs | Zolnox | Zolpidem lasca</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Stilnox | Zolonia | Zolpigen</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Hypnogen | Ladinox | Zolpidem | Zolpidem Actavis | Zolpidem al | Zolpidem atb</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ivadal | Nitrest | Sanval | Zolpidem | Zolsana | Zonadin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Zolonia | Zolpigen</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Edluar | Stilnoct | Zolpidem Actavis | Zolpidem alpharma | Zolpidem aurobindo | Zolpidem dune | Zolpidem hexal | Zolpidem merck nm | Zolpidem mylan | Zolpidem orifarm | Zolpidem ratiopharm | Zolpidem sandoz | Zolpidem stada | Zolpidem vitabalans | Zolpidem winthrop</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Stilnox</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Perluna | Sanval | Zolpidem vitabalans | Zolsana | Zonadin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Adorma | Hypnogen | Sanval | Stilnox | Zolpidem Orion | Zolpidem teva | Zolpidem vitabalans | Zolpidem xantis | Zolpinox</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Dactive | Stilnox | Zolpidem Apotex | Zopim</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Somex | Stilnox | Zolpidem mylan | Zolpinox</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dactive | Leyoumian | Rapnotic | Semi-Nax | Sleepman | Stilnox | Stimin | Zipsoon | Zodem | Zodenox | Zoldem | Zoldox | Zolman | Zolnox | Zolpi | Zolpidem cyh | Zopidem | Zopim | Zopimen | Zorimin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ivadal</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dormilan | Durnit | Somit | Stilnox | Sucedal | Zolnox</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Atrimon | Stilnox | Zolpidex</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco-zolpidem | Ivedal | Medploz | Noxidem | Nyxe | Stilnox | Zolnoxs | Zolpidem | Zolpihexal | Zoltab</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Zolpihexal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity.<i> Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ambien.1">
<a name="Ambien.1"></a>Ambien (zolpidem tartrate tablet) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AmbienCR.1">
<a name="AmbienCR.1"></a>Ambien CR (zolpidem tartrate extended-release tablet) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30693946">
<a name="30693946"></a>American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2019;67(4):674-694. doi:10.1111/jgs.15767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/30693946/pubmed" id="30693946" target="_blank">30693946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28391425">
<a name="28391425"></a>Anand S, Tong H, Besag FMC, Chan EW, Cortese S, Wong ICK. Safety, tolerability and efficacy of drugs for treating behavioural insomnia in children with attention-deficit/hyperactivity disorder: a systematic review with methodological quality assessment. <i>Paediatr Drugs</i>. 2017;19(3):235-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/28391425/pubmed" id="28391425" target="_blank">28391425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20607118">
<a name="20607118"></a>Bélanger L, Belleville G, Morin C. Management of hypnotic discontinuation in chronic insomnia. <i>Sleep Med Clin.</i> 2009;4(4):583-592. doi: 10.1016/j.jsmc.2009.07.011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/20607118/pubmed" id="20607118" target="_blank">20607118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Beyraghi.2016">
<a name="Beyraghi.2016"></a>Beyraghi N, Shamsi A, Farrokhian A. Detoxification of high-dose zolpidem using phenobarbital and gabapentin: two case reports. <i>Archives of Psychiatry and Psychotherapy</i>. 2016;4:16-19. doi:10.12740/APP/66307</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19403468">
<a name="19403468"></a>Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age. <i>Pediatrics</i>. 2009;123(5):e770-e776. doi:10.1542/peds.2008-2945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/19403468/pubmed" id="19403468" target="_blank">19403468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17957186">
<a name="17957186"></a>Blumer JL, Reed MD, Steinberg F, et al, "Potential Pharmacokinetic Basis for Zolpidem Dosing in Children With Sleep Difficulties," <i>Clin Pharmacol Ther</i>, 2008, 83(4):551-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/17957186/pubmed" id="17957186" target="_blank">17957186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27318232">
<a name="27318232"></a>Booth JN 3<sup>rd</sup>, Behring M, Cantor RS, et al. Zolpidem use and motor vehicle collisions in older drivers. <i>Sleep Med</i>. 2016;20:98-102. doi:10.1016/j.sleep.2015.12.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/27318232/pubmed" id="27318232" target="_blank">27318232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28921528">
<a name="28921528"></a>Bruni O, Angriman M, Calisti F, et al. Practitioner review: treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities. <i>J Child Psychol Psychiatry</i>. 2018;59(5):489-508. doi:10.1111/jcpp.12812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/28921528/pubmed" id="28921528" target="_blank">28921528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21480377">
<a name="21480377"></a>Chang CM, Chen MJ, Tsai CY, et al. Medical conditions and medications as risk factors of falls in the inpatient older people: a case-control study. <i>Int J Geriatr Psychiatry</i>. 2011;26(6):602-607. doi:10.1002/gps.2569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/21480377/pubmed" id="21480377" target="_blank">21480377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25470097">
<a name="25470097"></a>Chen CS, Huang MF, Hwang TJ, et al. Clinical correlates of zolpidem-associated complex sleep-related behaviors: age effect. <i>J Clin Psychiatry</i>. 2014;75(11):e1314-e1318. doi:10.4088/JCP.13m08901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/25470097/pubmed" id="25470097" target="_blank">25470097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23352047">
<a name="23352047"></a>Chopra A, Selim B, Silber MH, Krahn L. Para-suicidal amnestic behavior associated with chronic zolpidem use: implications for patient safety. <i>Psychosomatics</i>. 2013;54(5):498-501. doi:10.1016/j.psym.2012.10.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/23352047/pubmed" id="23352047" target="_blank">23352047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23826304">
<a name="23826304"></a>Chung SD, Lin CC, Wang LH, Lin HC, Kang JH. Zolpidem use and the risk of injury: a population-based follow-up study. <i>PLoS One</i>. 2013;8(6):e67459. doi:10.1371/journal.pone.0067459<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/23826304/pubmed" id="23826304" target="_blank">23826304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26201171">
<a name="26201171"></a>Cronin SD, Gottschlich MM, Gose LM, Kagan RJ. Zolpidem and sleep in pediatric burn patients with attention deficit/hyperactivity disorder. <i>Pediatr Nurs</i>. 2015;41(3):132-134, 140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/26201171/pubmed" id="26201171" target="_blank">26201171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cubala.2014">
<a name="Cubala.2014"></a>Cubala WJ, Gabrielsson A. Sleep related amnestic behaviors due to zolpidem. Bulletin of Clinical Psychopharmacology. 2014;24(2):188-194. doi:10.5455/bcp.20130527020102</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Edluar.1">
<a name="Edluar.1"></a>Edluar (zolpidem tartrate) sublingual tablet [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc,FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA Drug Safety Communication. Risk of next‐morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). Food and Drug Administration website. <a href="https://www.fda.gov/files/drugs/published/Drug-Safety-Communication--Risk-of-next-morning-impairment-after-use-of-insomnia-drugs--FDA-requires-lower-recommended-doses-for-certain-drugs-containing-zolpidem-%28Ambien--Ambien-CR--Edluar--and-Zolpimist%29.pdf" target="_blank">https://www.fda.gov/files/drugs/published/Drug-Safety-Communication--Risk-of-next-morning-impairment-after-use-of-insomnia-drugs--FDA-requires-lower-recommended-doses-for-certain-drugs-containing-zolpidem-%28Ambien--Ambien-CR--Edluar--and-Zolpimist%29.pdf</a>. January 10, 2013. Accessed March 3, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>FDA Safety Alert. MedWatch. FDA adds Boxed Warnings for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines. Food and Drug Administration website. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia</a>. Accessed May 3, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8458597">
<a name="8458597"></a>Fillastre JP, Geffroy-Josse S, Etienne I, et al. Pharmacokinetics and pharmacodynamics of zolpidem following repeated doses in hemodialyzed uraemic patients. <i>Fundam Clin Pharmacol.</i> 1993;7(1):1-9. doi:10.1111/j.1472-8206.1993.tb00212.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/8458597/pubmed" id="8458597" target="_blank">8458597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17101746">
<a name="17101746"></a>Greenblatt DJ, Legangneux E, Harmatz JS, et al. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. <i>J Clin Pharmacol</i>. 2006;46(12):1469-1480. doi:10.1177/0091270006293303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/17101746/pubmed" id="17101746" target="_blank">17101746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23541711">
<a name="23541711"></a>Greenblatt DJ, Harmatz JS, Roth T, et al. Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. <i>Clin Ther</i>. 2013;35(5):604-611. doi:10.1016/j.clinthera.2013.03.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/23541711/pubmed" id="23541711" target="_blank">23541711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grzegorzewska.2020">
<a name="Grzegorzewska.2020"></a>Grzegorzewska AM, Landowski JJ, Cubala WJ. Clinical considerations of sleep related amnestic behaviours associated with zolpidem. <i>Farmakoterapia w Psychiatrii i Neurologii</i>. 2020;36(1):23–31. doi:10.33450/fpn.2020.04.001</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23456542">
<a name="23456542"></a>Gunja N. In the Zzz zone: the effects of Z-drugs on human performance and driving. <i>J Med Toxicol</i>. 2013;9(2):163-171. doi:10.1007/s13181-013-0294-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/23456542/pubmed" id="23456542" target="_blank">23456542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25763219">
<a name="25763219"></a>Haji Seyed Javadi SA, Hajiali F, Nassiri-Asl M. Zolpidem dependency and withdrawal seizure: a case report study. <i>Iran Red Crescent Med J</i>. 2014;16(11):e19926. doi:10.5812/ircmj.19926<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/25763219/pubmed" id="25763219" target="_blank">25763219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30328648">
<a name="30328648"></a>Hanna AH, Ramsingh D, Sullivan-Lewis W, et al. A comparison of midazolam and zolpidem as oral premedication in children, a prospective randomized double-blinded clinical trial [published online October 17, 2018]. <i>Paediatr Anaesth</i>. 2018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/30328648/pubmed" id="30328648" target="_blank">30328648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32323442">
<a name="32323442"></a>Harbourt K, Nevo ON, Zhang R, Chan V, Croteau D. Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death. <i>Pharmacoepidemiol Drug Saf</i>. 2020;29(6):684-691. doi:10.1002/pds.5004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/32323442/pubmed" id="32323442" target="_blank">32323442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ho.2020">
<a name="Ho.2020"></a>Ho T, Jimenez A, Sanchez I, Seeger C, Joseph M. Sleep-related eating disorder associated with zolpidem: cases compiled from a literature review. <i>Sleep Medicine: X. </i>2020;2:100019. doi:10.1016/j.sleepx.2020.100019</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10804040">
<a name="10804040"></a>Holm KJ and Goa KL, “Zolpidem: An Update of Its Pharmacology, Therapeutic Efficacy and Tolerability in the Treatment of Insomnia,” <i>Drugs</i>, 2000, 59(4):865-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/10804040/pubmed" id="10804040" target="_blank">10804040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20441722">
<a name="20441722"></a>Hwang TJ, Ni HC, Chen HC, Lin YT, Liao SC. Risk predictors for hypnosedative-related complex sleep behaviors: a retrospective, cross-sectional pilot study. <i>J Clin Psychiatry</i>. 2010;71(10):1331-1335. doi:10.4088/JCP.09m05083bro<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/20441722/pubmed" id="20441722" target="_blank">20441722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21494350">
<a name="21494350"></a>Inagaki T, Miyaoka T, Tsuji S, Inami Y, Nishida A, Horiguchi J. Adverse reactions to zolpidem: case reports and a review of the literature. <i>Prim Care Companion J Clin Psychiatry</i>. 2010;12(6):PCC.09r00849. doi:10.4088/PCC.09r00849bro<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/21494350/pubmed" id="21494350" target="_blank">21494350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Intermezzo.1">
<a name="Intermezzo.1"></a>Intermezzo (zolpidem tartrate tablet) [prescribing information]. Stamford, CT: Purdue Pharma LP; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22673707">
<a name="22673707"></a>Jones AW, Holmgren A. Concentrations of zolpidem and zopiclone in venous blood samples from impaired drivers compared with femoral blood from forensic autopsies. <i>Forensic Sci Int</i>. 2012;222(1-3):118-123. doi:10.1016/j.forsciint.2012.05.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/22673707/pubmed" id="22673707" target="_blank">22673707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19657707">
<a name="19657707"></a>Juric S, Newport DJ, Ritchie JC, Galanti M, Stowe ZN. Zolpidem (Ambien) in pregnancy: placental passage and outcome. <i>Arch Womens Ment Health.</i> 2009;12(6):441-446.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/19657707/pubmed" id="19657707" target="_blank">19657707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23165956">
<a name="23165956"></a>Kolla BP, Lovely JK, Mansukhani MP, Morgenthaler TI. Zolpidem is independently associated with increased risk of inpatient falls. <i>J Hosp Med</i>. 2013;8(1):1-6. doi:10.1002/jhm.1985<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/23165956/pubmed" id="23165956" target="_blank">23165956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15486596">
<a name="15486596"></a>McCall WV. Sleep in the elderly: burden, diagnosis, and treatment. <i>Prim Care Companion J Clin Psychiatry</i>. 2004;6(1):9-20. doi:10.4088/pcc.v06n0104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/15486596/pubmed" id="15486596" target="_blank">15486596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27609243">
<a name="27609243"></a>McCall WV, Benca RM, Rosenquist PB, et al. Hypnotic medications and suicide: risk, mechanisms, mitigation, and the FDA. <i>Am J Psychiatry</i>. 2017;174(1):18-25. doi:10.1176/appi.ajp.2016.16030336<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/27609243/pubmed" id="27609243" target="_blank">27609243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30674203">
<a name="30674203"></a>McDonagh MS, Holmes R, Hsu F. Pharmacologic treatments for sleep disorders in children: a systematic review. <i>J Child Neurol</i>. 2019;34(5):237-247. doi:10.1177/0883073818821030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/30674203/pubmed" id="30674203" target="_blank">30674203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12919178">
<a name="12919178"></a>Olubodun JO, Ochs HR, von Moltke LL, et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. <i>Br J Clin Pharmacol</i>. 2003;56(3):297-304. doi:10.1046/j.0306-5251.2003.01852.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/12919178/pubmed" id="12919178" target="_blank">12919178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2612539">
<a name="2612539"></a>Pons G, Francoual C, Guillet P, et al. Zolpidem excretion in breast milk. <i>Eur J Clin Pharmacol</i>. 1989;37(3):245-248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/2612539/pubmed" id="2612539" target="_blank">2612539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27136449">
<a name="27136449"></a>Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. <i>Ann Intern Med.</i> 2016;165(2):125-133. doi: 10.7326/M15-2175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/27136449/pubmed" id="27136449" target="_blank">27136449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26243852">
<a name="26243852"></a>Ram D, Eiman N, Gowdappa B. Multimodal hallucination (audio-visual, kinaesthetic and scenic) associated with the use of zolpidem. <i>Clin Psychopharmacol Neurosci</i>. 2015;13(2):215-217. doi:10.9758/cpn.2015.13.2.215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/26243852/pubmed" id="26243852" target="_blank">26243852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28875581">
<a name="28875581"></a>Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. <i>J Sleep Res.</i> 2017;26(6):675-700. doi: 10.1111/jsr.12594.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/28875581/pubmed" id="28875581" target="_blank">28875581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32543994">
<a name="32543994"></a>Russo AD, Hodgman M, Calleo V. Seizures secondary to zolpidem withdrawal. <i>Clin Toxicol (Phila)</i>. 2021;59(2):174-175. doi:10.1080/15563650.2020.1778718<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/32543994/pubmed" id="32543994" target="_blank">32543994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34935466">
<a name="34935466"></a>Saito J, Tachibana Y, Sano Wada Y, et al. Presence of hypnotics in the cord blood and breast milk, with no adverse effects in the infant: a case report. <i>Breastfeed Med</i>. 2021. doi:10.1089/bfm.2021.0321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/34935466/pubmed" id="34935466" target="_blank">34935466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30722037">
<a name="30722037"></a>Schifano F, Chiappini S, Corkery JM, Guirguis A. An insight into Z-drug abuse and dependence: an examination of reports to the European Medicines Agency database of suspected adverse drug reactions. <i>Int J Neuropsychopharmacol</i>. 2019;22(4):270-277. doi:10.1093/ijnp/pyz007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/30722037/pubmed" id="30722037" target="_blank">30722037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15841201">
<a name="15841201"></a>Sharma A, Dewan VK. A case report of zolpidem-induced somnambulism. <i>Prim Care Companion J Clin Psychiatry</i>. 2005;7(2):74. doi:10.4088/pcc.v07n0207a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/15841201/pubmed" id="15841201" target="_blank">15841201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21385155">
<a name="21385155"></a>Sharma A, Sayeed N, Khees CR, Akhtar S. High dose zolpidem induced fetal neural tube defects. <i>Curr Drug Saf</i>. 2011;6(2):128-129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/21385155/pubmed" id="21385155" target="_blank">21385155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity.<i> Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24931450">
<a name="24931450"></a>Stranks EK, Crowe SF. The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. <i>J Clin Exp Neuropsychol</i>. 2014;36(7):691-700. doi:10.1080/13803395.2014.928268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/24931450/pubmed" id="24931450" target="_blank">24931450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sublinox.1">
<a name="Sublinox.1"></a>Sublinox (zolpidem) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SAMHSA.1">
<a name="SAMHSA.1"></a>Substance Abuse and Medical Health Services Administration (SAMHSA). Drug Abuse Warning Network. Emergency department visits attributed to overmedication that involved the insomnia medication zolpidem. <a href="https://www.samhsa.gov/data/sites/default/files/DAWN-SR150-Zolpidem-2014/DAWN-SR150-Zolpidem-2014.htm" target="_blank">https://www.samhsa.gov/data/sites/default/files/DAWN-SR150-Zolpidem-2014/DAWN-SR150-Zolpidem-2014.htm</a>. August 7, 2014. Accessed March 3, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26776243">
<a name="26776243"></a>Sun Y, Lin CC, Lu CJ, Hsu CY, Kao CH. Association between zolpidem and suicide: a nationwide population-based case-control study. <i>Mayo Clin Proc</i>. 2016;91(3):308-315. doi:10.1016/j.mayocp.2015.10.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/26776243/pubmed" id="26776243" target="_blank">26776243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29077902">
<a name="29077902"></a>Treves N, Perlman A, Kolenberg Geron L, Asaly A, Matok I. Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis. <i>Age Ageing</i>. 2018;47(2):201-208. doi:10.1093/ageing/afx167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/29077902/pubmed" id="29077902" target="_blank">29077902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22607251">
<a name="22607251"></a>Verster JC, Roth T. Gender differences in highway driving performance after administration of sleep medication: a review of the literature. <i>Traffic Inj Prev</i>. 2012;13(3):286-292. doi:10.1080/15389588.2011.652751<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/22607251/pubmed" id="22607251" target="_blank">22607251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11844004">
<a name="11844004"></a>Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Zolpidem use and hip fractures in older people. <i>J Am Geriatr Soc</i>. 2001;49(12):1685-1690. doi:10.1111/j.1532-5415.2001.49280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/11844004/pubmed" id="11844004" target="_blank">11844004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20686480">
<a name="20686480"></a>Wang LH, Lin HC, Lin CC, Chen YH, Lin HC. Increased risk of adverse pregnancy outcomes in women receiving zolpidem during pregnancy. <i>Clin Pharmacol Ther. </i>2010;88(3):369-374.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/20686480/pubmed" id="20686480" target="_blank">20686480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21448102">
<a name="21448102"></a>Wang LJ, Ree SC, Chu CL, Juang YY. Zolpidem dependence and withdrawal seizure--report of two cases. <i>Psychiatr Danub</i>. 2011;23(1):76-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/21448102/pubmed" id="21448102" target="_blank">21448102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834190">
<a name="31834190"></a>Westermeyer J, Carr TM. Zolpidem-associated consequences: an updated literature review with case reports. <i>J Nerv Ment Dis</i>. 2020;208(1):28-32. doi:10.1097/NMD.0000000000001074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/31834190/pubmed" id="31834190" target="_blank">31834190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21508851">
<a name="21508851"></a>Wikner BN, Källén B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans? <i>J Clin Psychopharmacol. </i>2011;31(3):356-359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/21508851/pubmed" id="21508851" target="_blank">21508851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31271339">
<a name="31271339"></a>Wilson S, Anderson K, Baldwin D, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. <i>J Psychopharmacol</i>. 2019;33(8):923-947. doi:10.1177/0269881119855343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/31271339/pubmed" id="31271339" target="_blank">31271339</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Zolpidem capsules [prescribing information]. Morristown, NJ: Almatica Pharma LLC; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zolpimist.1">
<a name="Zolpimist.1"></a>Zolpimist oral spray (zolpidem tartrate) [prescribing information]. Englewood, CO: Aytu BioScience, Inc.; February 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13094 Version 603.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
